PDF is committed to using your funds efficiently to support our mission. To see how funds are spent, browse our financial information.
APT Update – Survey: Few Know of PD Trials
Survey: Few Know of PD Trials
A recent survey shows that although interest in clinical trials among people with Parkinson's disease and their physicians is high, awareness of such opportunities remains low. This information was revealed in a nationwide survey conducted by Harris Interactive® on behalf of Advancing Parkinson's Therapies (APT), a campaign representing all of the major voluntary PD organizations. The survey was funded through the Michael J. Fox Foundation for Parkinson's Research.
The survey showed that nearly 80 percent of people with PD would be likely to participate in a clinical trial if one were available in their area. Yet only 11 percent of them report that their doctor has suggested that they participate in a trial and the majority of physicians report that the issue of clinical trials comes up with 10 percent or less of their patients. This lack of communication may be attributed to low awareness and education, since only 18 percent of patients reported that they are somewhat or very satisfied with the amount of information available about clinical trials for PD.
PD patients also expressed concerns about participating in clinical trials, including not wishing to volunteer if their PD is well-controlled, the possibility of undergoing painful tests or procedures, the potential time commitment, the likelihood that they might receive a placebo and concerns about whether they would have continued access to a medication once a trial has been concluded.
APT will use this information to tailor its efforts to increase awareness and education about clinical trials. For more information on APT and to view a list of trials that are still enrolling patients, visit www.PDtrials.org.
APT is led by PDF in collaboration with the American Parkinson Disease Association, The Michael J. Fox Foundation for Parkinson's Research, the National Parkinson Foundation, the Parkinson's Action Network, the Parkinson Alliance, WE MOVE, and is advised by NINDS, the Parkinson Study Group and the Parkinson Pipeline Project.